IVIG treatment for BK virus after kidney transplant
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 3 trial tests IVIG (an antibody medicine given through a vein) to treat BK virus infection after kidney or pancreas-kidney transplant. It may help lower the BK virus in the blood and protect the transplanted kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 2 or older
- You had a kidney transplant or simultaneous pancreas-kidney transplant
- You have BK virus in the blood at a certain level, or evidence of BK virus seen in biopsy results, within the last 3 weeks
- A parent/guardian can consent for children under 18 (or you can consent yourself)
- You cannot have major reasons you can’t safely receive IVIG
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how often BK virus shows up in people after a combined liver-kidney transplant. It may help the transplant team better predict and manage this virus after surgery.
This study tests a new medicine (AIC468) to see if it can help clear BK virus from the blood of people who have recently had a kidney transplant. Participants will receive either the study drug or a placebo (a dummy pill) to compare outcomes.
This study is creating a registry to learn how the immune system responds to BK virus in people who have recently received a kidney transplant from a deceased donor. Researchers hope this information will help improve treatment for BK virus infections.
This Phase 1/2 study tests lab-made immune cells that specifically target BK virus in people whose BK infection keeps coming back or doesn’t improve. It may help by boosting the body’s ability to clear the virus, especially when standard antiviral treatments don’t work or can’t be tolerated.
This early-phase study tests whether immune cells made from a donor (T cells) can treat BK virus infection in people whose immune system is weak after a stem cell transplant or chemotherapy. It may help control the virus causing bladder/urinary symptoms.
This study looks at the type and genetic makeup of BK virus in kidney transplant patients and their donors. It aims to find patients at higher risk for a kidney infection caused by the virus, which could help improve monitoring and treatment.
Hear when a new Kidney Transplant Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.